As demand for biological drugs increases, so does the need for purified protein. Whether for research or to create biotherapeutics, researchers must purify protein following expression and scale-up.

From the earlier regulatory successes of Adcetris® and Kadcyla® to the recent FDA approval of Blincyto®, to the current clinical successes of Opdivo® and Keytruda®, the industry is abuzz with excitement and new hope.

Once again PEGS Europe showcases current advances with bispecifics with presentations across several tracks from academic and industry pioneers in the field.

PEGS Europe is the largest European event covering all aspects of protein and antibody engineering will be called on 31 October - 4 November 2016 at Lisbon Portugal. Over the last three years, participation at PEGS Europe has grown by more than 60%, and t

Knowing Korea scientists’ strong interest in this field among its burgeoning biotech companies, CHI is pleased to introduce our Cancer Immunotherapy conference, as part of the 2nd Annual PEGS Korea. We invite international and domestic companies to share t

Pre-registration numbers are up significantly for the upcoming PEGS Summit taking place April 25-29 at The Seaport World Trade Center in Boston.

Leading European Event for Protein & Antibody Engineering Returns to Lisbon after Record Attendance